AstraZeneca ( (GB:AZN) ) has shared an update.
AstraZeneca’s Imfinzi, in combination with chemotherapy, has been recommended for approval by the CHMP in the EU for treating adults with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence. This recommendation is based on the AEGEAN Phase III trial results, which demonstrated a 32% reduction in the risk of recurrence, progression, or death compared to neoadjuvant chemotherapy alone. The approval could significantly enhance AstraZeneca’s position in the oncology market, providing a new treatment option for patients with early-stage lung cancer, addressing a high unmet medical need.
More about AstraZeneca
AstraZeneca is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in oncology, cardiovascular, renal, and metabolism, and respiratory and immunology. The company is committed to advancing science to improve patient outcomes and has a strong presence in the lung cancer treatment market with a comprehensive portfolio of medicines.
YTD Price Performance: 15.99%
Average Trading Volume: 2,726,207
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: £185.6B
For detailed information about AZN stock, go to TipRanks’ Stock Analysis page.